Why Is Omniab Stock Rallying After Eli Lilly Deal?
OmniAb, Inc. (NASDAQ: OABI) shares surged after the company announced a global collaboration and license agreement with Eli Lilly and Company (NYSE: LLY) for an ion channel program. The deal includes an upfront payment and up to $370 million in potential milestone payments, along with tiered royalties. OmniAb also raised its 2026 cash outlook due to recent licensing activity, now expecting $49 million to $53 million in cash and cash equivalents.
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook
OmniAb Inc. (OABI) shares surged nearly 18% after the company increased its 2026 cash forecast due to new licensing agreements, including one with Eli Lilly for its ion-channel program. This improved outlook provides OmniAb with greater financial stability, reducing immediate dilution risks and enabling continued investment in its antibody discovery technologies. The key challenge for OmniAb remains translating its platform into substantial long-term licensing fees and milestones to maintain its cash position.
Eli Lilly Signs $370 Million Ion Channel Deal With OmniAb, Sending Shares Surging
Eli Lilly has inked a global collaboration and license agreement with OmniAb for a new ion channel program, a deal potentially worth up to $370 million in milestone payments and tiered royalties. The news sent OmniAb's shares surging in premarket trading. OmniAb also updated its 2026 cash outlook upward due to recent licensing activity.
OABI Reiterates by HC Wainwright & Co. -- Price Target Maintained at $11.00
HC Wainwright & Co. has reiterated a "Buy" rating for OmniAb (OABI) with a maintained price target of $11.00, signaling confidence despite the stock being currently overvalued at $3.92 against a GF Value™ of $2.92. OmniAb's GF Score™ is 70/100, indicating moderate overall performance with strengths in financial stability and momentum but weaknesses in profitability. Investors are advised to exercise caution due to the overvaluation and the company's unprofitable status.
Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m
OmniAb has signed a global collaboration and license agreement with Eli Lilly for an ion channel program, potentially bringing OmniAb up to $370 million in milestone payments and royalties. While OmniAb will handle the discovery phase using its specialized platform for difficult-to-target ion channels, Lilly will retain global rights and manage development and commercialization. This deal expands OmniAb's platform-licensing model, which has already led to approved therapeutics, further solidifying its role as a pure-play discovery platform licensor.
OmniAb, Inc. And Eli Lilly And Company Announce Global Collaboration And License Agreement For Ion Channel Program
OmniAb, Inc. has announced a global collaboration and license agreement with Eli Lilly and Company focused on a new ion channel program. This agreement grants OmniAb an upfront payment and eligibility for up to $370 million in research, development, and commercial milestone payments, along with tiered royalties on global net sales. The collaboration leverages OmniAb's technology platform for ion channel discovery and screening.
OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook
OmniAb Inc. (OABI) saw its stock jump by 21.6% after reporting a strong Q2, beating EPS estimates by $0.08 and nearly tripling revenue expectations. The company also raised its 2026 revenue guidance to $32M–$36M and completed discovery work on a key collaboration, positioning it for future revenue without additional R&D spend. This financial strength and positive outlook have made OABI a notable momentum play for active traders.
OmniAb Inc. Stock Pops As Earnings Beat Fuels Guidance Hike
OmniAb Inc. (NASDAQ: OABI) saw its stock price surge by 21.6% after reporting a strong Q2 earnings beat, exceeding EPS estimates by $0.08 and nearly tripling revenue expectations. The company also raised its 2026 revenue guidance to $32M–$36M, up from previous estimates, and announced the completion of discovery work on a key collaboration with Veraxa Biotech. This positive news, coupled with a solid balance sheet, positions OABI as a notable momentum play for traders.
OmniAb (OABI) Stock Surges After Big Q2 Earnings Beat
OmniAb (OABI) stock surged over 17% following a significant beat on its Q2 earnings, with EPS exceeding expectations by $0.08 and revenue nearly tripling Wall Street forecasts. The company also raised its FY26 revenue outlook to $32M–$36M and completed discovery work on a bispecific antibody-drug conjugate with Veraxa Biotech, retaining future revenue rights. This performance has positioned OABI as a high-volatility, news-driven stock drawing significant attention from momentum traders.
OmniAb partners with Eli Lilly on ion channel program By Investing.com
OmniAb, Inc. announced a global collaboration and license agreement with Eli Lilly and Company for an ion channel drug discovery program. The agreement includes an upfront payment to OmniAb, eligibility for up to $370 million in milestone payments, and tiered royalties on global net sales. This partnership will leverage OmniAb’s technology platform and expertise in ion channel discovery to develop new medicines.
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company
OmniAb has announced a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program. This agreement leverages OmniAb's technology platform and expertise in ion channel discovery and screening. Under the terms, OmniAb will receive an upfront payment and is eligible for up to $370 million in milestone payments, plus tiered royalties on global net sales.
Whitefort Capital group reports 7.1% OmniAb (OABI) ownership in amended filing
Whitefort Capital Management, along with David Salanic and Joseph Kaplan, has reported a beneficial ownership of 7.1% in OmniAb, Inc. (OABI) through an amended Schedule 13G filing. This group beneficially owns 10,248,658 shares, representing 7.1% of OmniAb's outstanding shares as of June 30, 2026. The shares are held in client accounts managed by Whitefort Capital Management, with shared voting and dispositive power among the reporting persons.
OmniAb (OABI) Q2 2026 Earnings Call Transcript
OmniAb (OABI) reported strong Q2 2026 financial results, with revenue reaching $13.4 million, primarily driven by milestone achievements from clinical program advancements. The company raised its full-year 2026 revenue guidance to $32 million to $36 million and expects to end the year with $37 million to $41 million in cash. The earnings call highlighted the growth in active partners and programs, clinical advancements of its partnered pipeline, and the increasing potential for future milestone payments and royalties from its differentiated antibody discovery technologies and xPloration instrument sales.
Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI
Dimensional Fund Advisors LP significantly reduced its stake in OmniAb, Inc. by 18.9% in the first quarter, although it still holds 1.75 million shares valued at $2.74 million. OmniAb exceeded analyst expectations with its recent earnings report, posting a smaller-than-expected loss and higher revenue, yet remains unprofitable. The stock has a "Hold" consensus rating from analysts, with institutional investors owning a substantial 72.08% of the company.
OABI Earning Date, Earning Analysis and Earning Prediction
This article provides an analysis and prediction of OABI's earnings, focusing on past results, analyst forecasts for 2026/Q3, and the correlation between earning revisions and stock price movements. It details OABI's recent earnings reports, including revenue and EPS surprises, and discusses the typical stock price reaction around earnings announcements. The article concludes with an overview of the sentiment from OmniAb Inc's Q1 2026 earnings call, highlighting optimism for future growth and efficiency.
New Forecasts: Here's What Analysts Think The Future Holds For OmniAb, Inc. (NASDAQ:OABI)
Analysts have significantly upgraded their statutory estimates for OmniAb, Inc. (NASDAQ:OABI), increasing revenue forecasts to US$35m for 2026 and reducing the estimated loss per share to US$0.36. This positive outlook follows a 69% surge in the company's share price over the past week. Despite the optimism, the company's revenue is still expected to decline at an accelerated rate compared to the broader industry.
New Forecasts: Here's What Analysts Think The Future Holds For OmniAb, Inc. (NASDAQ:OABI)
Analysts have significantly upgraded their statutory estimates for OmniAb, Inc. (OABI), increasing revenue forecasts and reducing expected losses for 2026. Despite the positive adjustments, the company is still projected to experience a revenue decline faster than the broader industry, although the reduced loss estimates suggest a gradual move towards profitability. The market reacted positively to the news, with the share price increasing by 69% in the last week.
New Forecasts: Here's What Analysts Think The Future Holds For OmniAb, Inc. (NASDAQ:OABI)
Analysts have significantly upgraded their statutory estimates for OmniAb, Inc. (NASDAQ:OABI), increasing revenue forecasts and reducing expected per-share losses for 2026. This positive revision comes after the company's share price recently gained 69%, indicating increased market optimism. Despite the upgrades, OmniAb's revenues are still projected to decline at an accelerated rate compared to the broader industry.
Price to sales forward of OmniAb, Inc. – NASDAQ:OABIW
This article provides the "Price to sales forward" metric for OmniAb, Inc. (NASDAQ: OABIW), a company listed on the Nasdaq Stock Market. The content appears to be a financial data snippet from a platform like TradingView, showing the period, value, and change for this specific financial ratio, indicating that the market was closed at the time of publication with no trades.
OmniAb (NASDAQ:OABI) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS
OmniAb (NASDAQ:OABI) reported its quarterly earnings, beating analyst expectations with an adjusted loss of $0.05 per share against an estimated $0.12 loss, and revenues of $13.41 million significantly surpassing estimates of $4.69 million. The company's Q2 revenue increased year-over-year, and its net loss narrowed, driven by partner milestone revenue. OmniAb also raised its 2026 revenue guidance to $32 million–$36 million, though analysts maintain a "Hold" rating due to revenue dependence on milestone timing.
OmniAb, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:OABI) 2026-08-07
OmniAb, Inc. (OABI) has released its Q2 2026 earnings call presentation. The company reported an EPS of -$0.05, which beat estimates by $0.08, and revenue of $13.42 million, exceeding expectations by $8.72 million and representing a 244.24% year-over-year increase. The slide deck provides details related to these financial results.
OmniAb, Inc. 1H 2026: Revenue $27.8M, EPS ($0.05) — 10-Q Summary
OmniAb, Inc. (OABI) reported a significant increase in revenue for the first half of 2026, reaching $27.8 million, up from $3.9 million in the prior comparable period. This growth was primarily driven by license and milestone receipts. Despite remaining net loss-making, the diluted loss per share improved to ($0.05) from ($0.15), and the company highlighted reduced R&D and G&A expenses following 2025 reorganizations.
OmniAb Q2 2026 Earnings Call Transcript
OmniAb (NASDAQ: OABI) reported strong Q2 2026 results, with revenue increasing to $13.4 million from $3.9 million year over year, primarily driven by partner milestone revenue, and a narrowed net loss of $5.9 million. The company raised its 2026 guidance, forecasting revenue between $32 million and $36 million, and highlighted significant progress in its partnered pipeline with 425 active programs and new clinical entrants. OmniAb also emphasized the potential of its xPloration platform and its genetically engineered chicken antibody discovery technologies in driving future growth and revenue diversification.
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights
OmniAb, Inc. reported strong second-quarter 2026 financial results, with revenue significantly increasing to $13.4 million, driven by milestone revenue and growth in xPloration. The company raised its full-year 2026 revenue and cash outlook, expecting revenue between $32 million and $36 million. OmniAb also highlighted significant progress in partner programs, including advancements in clinical trials for several therapeutic candidates and the appointment of a new Chief Operating Officer.
OmniAb Inc (OABI) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of OmniAb Inc (OABI), detailing its current price momentum, support and resistance levels, and various technical indicator readings. The stock is currently trading between a resistance level of 2.43 and a support level of 1.98, suggesting suitability for range-bound swing trading. The analysis also includes a breakdown of buy, sell, and neutral signals from indicators like MACD, RSI, and different moving averages.
OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ...
OmniAb Inc (OABI) reported strong Q2 2026 results with a 243% revenue surge to $13.4 million, driven by higher milestone revenue and two programs advancing directly from Phase 1 to Phase 3. The company, which uses a unique transgenic chicken platform for human antibody sequences, improved its net loss to $5.9 million and raised its full-year revenue guidance to $32 million-$36 million. Despite reliance on milestone payments and operating at a net loss, OmniAb is seeing strong interest in its technologies and expects long-term growth through royalties and an expanding exploration platform.
OmniAb Q2 2026 slides: revenue surges 244%, guidance raised
OmniAb Inc. (NASDAQ:OABI) reported a significant 244% year-over-year revenue increase in Q2 2026, reaching $13.4 million, primarily driven by milestone payments and the xPloration instrument platform. This strong performance led the company to raise its full-year 2026 revenue guidance to $32 million to $36 million and improve its year-end cash balance outlook. OmniAb also expanded its partner network to 110 active partners and increased its clinical-stage pipeline to 34 programs, underscoring robust growth in its antibody discovery business.
OmniAb (NASDAQ: OABI) grows partner base and cuts cash burn in 2026
OmniAb Inc. reported a significant increase in revenue for Q2 and H1 2026, driven by license and milestone payments, while simultaneously reducing its net loss and cash burn from operations. The company expanded its partner base to 110 active partners and 425 active programs, reinforcing its financial stability with $52.0 million in cash and equivalents, sufficient to fund operations for at least 12 months. Despite a $2.9 million impairment charge on an intangible asset, OmniAb's strategic focus on its technology platform and partnerships is yielding positive financial improvements.
OmniAb (NASDAQ: OABI) boosts 2026 revenue guidance after strong Q2
OmniAb (NASDAQ: OABI) reported strong Q2 2026 results, with revenue reaching $13.4 million, significantly up from $3.9 million in Q2 2025, driven by milestone, service, and xPloration sales. The company narrowed its net loss to $5.9 million and raised its full-year 2026 revenue guidance to $32–$36 million, alongside an increased year-end cash outlook of $37–$41 million. OmniAb also highlighted active partnerships and advancements in multiple clinical programs, including several moving into or toward Phase 3 studies.
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates
OmniAb, Inc. (OABI) reported a Q2 loss of $0.05 per share, surpassing the Zacks Consensus Estimate of a $0.11 loss and significantly improving from a $0.15 loss a year ago. The company also
OmniAb (NASDAQ: OABI) awards 800,000 stock options to its COO
OmniAb, Inc. (NASDAQ: OABI) has granted its Chief Operating Officer, Nwachuku Amechi Ekeke, 800,000 stock options with an exercise price of $1.98 per share, expiring on August 1, 2036. The options will vest over 42 months, beginning August 1, 2026, contingent on Ekeke's continued employment. This transaction was reported via a Form 4 SEC filing, indicating it was not made under a Rule 10b5-1 plan.
OABIW Stock Warrant Price and Chart — NASDAQ:OABIW
This page provides an overview of OmniAb, Inc. (OABIW) stock warrant, including its market capitalization of $294.29 million, key financial figures like net income and revenue, and company details. OmniAb, Inc. is a drug discovery company specializing in human monoclonal and bispecific therapeutic antibodies, founded in 2015 and headquartered in Emeryville, CA. The platform utilizes biological intelligence from transgenic animals such as OmniRat, OmniChicken, and OmniMouse.
OABIW Stock Warrant Price and Chart — NASDAQ:OABIW
This article provides an overview of OmniAb, Inc. (OABIW), a drug discovery company focused on developing therapeutic antibodies. It includes key financial stats, upcoming earnings information, company details, and an embedded chart for price movements, indicating the market is currently closed with no trades.
Price to book forward of OmniAb, Inc. – NASDAQ:OABI
The article focuses on the "Price to book forward" metric for OmniAb, Inc. (NASDAQ: OABI). It appears to be a financial data point provided by TradingView, indicating specific values and changes over a period. The content primarily lists market and company information and disclaimers about data sources.
Number of shareholders of OmniAb, Inc. – NASDAQ:OABI
This article states that OmniAb, Inc. (NASDAQ: OABI) has "No trades" and provides general information about the company's financials, news, and community on the TradingView platform. It appears to be a stub or an incomplete page that only lists the company and market information, without specific details about the number of shareholders.
Enterprise value to revenue forward of OmniAb, Inc. – BOATS:OABI
This article provides an "Enterprise value to revenue forward" metric for OmniAb, Inc. (BOATS:OABI) on TradingView. It appears to be a financial data point rather than an in-depth analysis, presented within the platform's interface. The content primarily consists of navigation and boilerplate information from the TradingView website.
OmniAb Inc (OABI) Institutional Confidence
The article analyzes the institutional confidence in OmniAb Inc (OABI), noting its current institutional shareholding score of 5.00, placing it 132nd within the Biotechnology & Medical Research industry. Institutional shareholding has increased by 3.41% quarter-over-quarter, reaching 57.16%, with Bill Nygren | OAKMX being the largest institutional shareholder. The report also lists key institutional shareholders and their recent activity.
OmniAb, Inc. Revenue Breakdown – NASDAQ:OABIW
OmniAb, Inc. (NASDAQ:OABIW) generated $18.67 million in revenue last year, with its top-performing segment, License and Milestone, contributing $9.77 million. This is a decrease from $13.87 million in the previous year for the same segment. The United States was the primary source of revenue, accounting for the entire $18.67 million.
OABI|OmniAb Inc|Price:1.950|
This article provides a comprehensive analysis of OmniAb Inc (OABI) through its "TradingKey Stock Score." The company shows healthy fundamentals, high growth potential, and is considered fairly valued within the Biotechnology & Medical Research industry. Analysts have rated OABI as a "Buy" with a significant upside potential, despite its recent weak stock market performance.
Price to earnings forward of OmniAb, Inc. – NASDAQ:OABI
This article provides a financial overview of OmniAb, Inc. (NASDAQ: OABI), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a section of a larger financial data page on TradingView, indicating that the detailed financial data for this metric would be displayed within the specified period.
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate (bsADC) program, VXA-222, following a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). OmniAb successfully completed its discovery work, moving the VXA-222 program, which targets two tumor antigens with an "AND-gate" approach, into its next phase. VERAXA holds exclusive rights to develop and commercialize products from this collaboration.
VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
VERAXA Biotech (NASDAQ: VRXA) announced a significant advancement in its bispecific antibody-drug conjugate (bsADC) program, VXA-222, following the successful completion of discovery work by OmniAb. This collaboration aims to develop a precise treatment for solid tumors using an "AND-gate" approach, with VERAXA holding exclusive development and commercialization rights. OmniAb will receive a share of the specified revenue from resulting products.
Enterprise value to EBIT forward of OmniAb, Inc. – NASDAQ:OABI
This article focuses on the enterprise value to EBIT forward for OmniAb, Inc. (NASDAQ:OABI). It indicates that financial data for this metric is provided by FactSet Research Systems Inc. and market data by ICE Data Services.
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration
VERAXA Biotech (NASDAQ: VRXA) has advanced its bispecific antibody-drug conjugate (bsADC) program, VXA-222, reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). OmniAb completed its discovery work, moving the program to its next phase. VXA-222 is designed to target two tumor antigens using an "AND-gate" approach for improved precision in treating solid tumors.
Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone
Veraxa Biotech has advanced its bispecific antibody-drug conjugate (ADC) program, VXA-222, into the next development phase after OmniAb completed its antibody discovery work. This collaboration utilizes OmniAb's transgenic antibody discovery platform and Veraxa’s proprietary ADC linker and conjugation technology to create a dual-antigen "AND-gate" candidate, aiming to improve precision in solid tumor treatment. The VXA-222 program represents a powerful opportunity to develop a best-in-class bispecific ADC for solid tumor indications with high unmet medical needs.
OABI|OmniAb Inc|Price:2.030|
OmniAb Inc. (OABI) licenses discovery research technology to pharmaceutical and biotech companies, leveraging its OmniAb platform to identify optimal antibodies for drug development. The company utilizes engineered transgenic animals like OmniRat and OmniChicken to generate human sequence antibodies. OmniAb's top five shareholders include Mr. John L. Higgins, and as of Q1 2026, 345 institutions held shares, with service revenue being the largest source of income.
Veraxa advances cancer therapy program with OmniAb
Veraxa Biotech AG announced that its bispecific antibody-drug conjugate program, VXA-222, advanced to the next development phase after completing discovery work with OmniAb, Inc. The program targets solid tumors using AND-gate logic, combining OmniAb's antibody discovery technologies with Veraxa's linker technology. Veraxa holds exclusive rights for development and commercialization, with OmniAb receiving a share of future revenues.
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb
VERAXA Biotech announced the advancement of its bispecific ADC (bsADC) program VXA-222, developed in collaboration with OmniAb. This program, which uses an "AND-gate" logic to target solid tumors, has moved into its next phase following the successful completion of OmniAb's discovery work. VERAXA will now apply its proprietary linker technology and conjugation expertise to further develop the lead candidate and retain exclusive rights to commercialize products derived from the collaboration.
VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens
VERAXA Biotech announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program, developed in collaboration with OmniAb since May 2025, has achieved a key technical milestone and is advancing to the next phase after OmniAb concluded its discovery work. VXA-222 employs an “AND-gate” design to target two solid tumor antigens with a single molecule, combining OmniAb’s antibody discovery technologies with VERAXA’s proprietary linker and conjugation expertise. VERAXA holds exclusive development and commercialization rights, with OmniAb receiving a share of future revenues.
OmniAb Inc (OABI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for OmniAb Inc (OABI) across its business segments for various fiscal quarters and years. It highlights that the company's main revenue streams are service revenue, license and milestone revenue, royalty revenue, and xPloration revenue. The data is presented in a tabular format showing the revenue amount in USD and its proportion of the total.
